Aimed Bio KRX:0009K0KOSDAQ
에임드바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Aimed Bio reported revenue of ₩20.2bn, up 165.6% year on year, and operating profit of ₩8.5bn. Aimed Bio (에임드바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Aimed Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩20.2bn | +165.6% | ₩8.5bn | ₩10.9bn |
| Q1 2026 | ₩8.5bn | +437.5% | −₩4.0bn | −₩2.0bn |
| Q4 2025 derived | ₩38.0bn | +233.0% | ₩25.5bn | ₩34.9bn |
| Q3 2025 | ₩114m | +0.5% | −₩5.9bn | −₩5.2bn |
| Q2 2025 | ₩7.6bn | – | ₩2.2bn | −₩23.6bn |
| Q1 2025 | ₩1.6bn | – | −₩1.1bn | −₩1.1bn |
| Q4 2024 derived | ₩11.4bn | – | ₩8.4bn | ₩7.1bn |
| Q3 2024 | ₩114m | – | −₩4.6bn | −₩2.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Aimed Bio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Aimed Bio news Korean headlines
No articles yet.